Last reviewed · How we verify

Advanced-J — Portfolio Competitive Intelligence Brief

Advanced-J pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Angiotensin II receptor antagonists, Calcium channel blocker Angiotensin II receptor antagonists, Calcium channel blocker marketed

Therapeutic area mix

No therapeutic area data.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Advanced-J:

Cite this brief

Drug Landscape (2026). Advanced-J — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/advanced-j. Accessed 2026-05-15.

Related